Yan Zhou

Background: Breast cancer was the second most common cancer and the fifth leading cause of cancer deaths among women in China, with increasing trends. Evaluating breast cancer trends and predicting future burdens can inform prevention strategies. This study aimed to analyze the trends in female breast cancer incidence, mortality, and survival in Fujian Province, southeastern China, between 2011 and 2020, and to project the future burden through 2025. Methods: Population‐based cancer registry data from Fujian Province were collected during 2011–2020, with survival follow‐up extending through March 2022, covering approximately 2.59 million women. Age‐standardized incidence rates (ASIR) and mortality rates (ASMR) were calculated using Segi's world standard population. Temporal trends were assessed using Joinpoint regression analysis to determine average annual percentage change (AAPC). Relative survival were computed as the ratio of observed survival to expected survival. Autoregressive Integrated Moving Average (ARIMA) model was employed to predict incidence and mortality for 2021–2025. Results: During 2011–2020, 8047 female breast cancer cases and 1754 deaths were recorded. The ASIR increased from 19.34/100,000 to 38.73/100,000, with an AAPC of 7.4% (95% CI: 3.6%–11.4%). The ASMR increased from 3.37/100,000 to 6.19/100,000, with an AAPC of 8.3% (95% CI: 4.3%–12.4%). Rural areas showed more rapid increases in both incidence and mortality than in urban areas. In 2011–2014, 2015–2017, and 2018–2020, the age‐standardized 5‐year relative survival rates were 64.10% (95% CI: 59.85–68.02), 69.35% (95% CI: 64.62–73.57), and 72.94% (95% CI: 68.5–76.86), with higher survival in urban areas and younger age groups. The ARIMA models projected continued increases in both ASIR and ASMR through 2025, reaching 46.41/100,000 and 8.46/100,000, respectively. Conclusion: Breast cancer constitutes an escalating public health challenge in Fujian Province with disparities across age groups and urban and rural areas. Future strategies should prioritize healthcare equity and regional resource allocation to reduce mortality and enhance survival outcomes.

Objectives This study aimed to investigate the changes in the incidence and mortality trends of ovarian cancer (OC), cervical cancer (CC) and uterine cancer (UC) in the Fujian Province, southeastern China. Design Provincial, population-based, retrospective observational study. Setting Fujian province, southeastern China between 2011-2020. Participants From 2011 to 2020, 6178 new cases and 2037 deaths caused by 3 gynaecological cancers were eligible for analysis. Primary and secondary outcome measures The primary outcome measures were the incidence and mortality rates, including the age-standardised incidence rate (ASIR) and age-standardised mortality rate (ASMR), of three gynaecological cancers. The secondary outcome measure was the prevalence (average annual per cent changes (AAPC)). Results The incidence of all three gynaecological cancers increased from 2011 to 2020. CC had the slowest upward trend, with an AAPC of 2.54% over the period. However, it had the highest ASIR among the 3 cancers in 2020 (10.41/100 000). UC showed a rapid increase, with an AAPC of 15.15% from 2016 to 2020. While the mortality rate of UC remained stable, both CC and OC also exhibited rising trends, with the CC having the highest ASMR (3.05/100 000) in 2020. The ASMR for CC increased rapidly, with the highest AAPC of 5.51%. Conversely, changes in the ASMR for UC were not statistically significant (p=0.601). Moreover, high incidence rates were more common among perimenopausal women and older participants in the respective cancer groups where the increased mortality was observed. Conclusions Gynaecological cancer burden remains a public health issue in Fujian Province, with an increasing incidence. Improving the healthcare system and promoting a healthy lifestyle should be highlighted to reduce the cancer burden.

Purpose: Identifying disease burden and risk factors of bladder cancer and projecting its epidemiological trend in China, which can provide reference data to formulate measures for its management and prevention. Methods: We analyzed the incidence, mortality, and disability-adjusted life-years (DALYs) data of bladder cancer in China from 1990 to 2019 and predicted to 2030 based on the Global Burden of Disease Study 2019. We also estimated the proportion of risk factors contributing to bladder cancer DALYs. The average annual percentage change (AAPC) in both sexes was calculated to quantify the temporal trends. Results: In China, the age-standardized incidence rate of bladder cancer increased from 3.3/100,000 in 1990 to 5.16/100,000 in 2019 (AAPC of 1.47), while the age-standardized mortality rate and age-standardized DALYs rate declined slightly (AAPC of − 0.58 and − 0.65, respectively). The burden of bladder cancer increased with age, which reached a peak over 85 years old. The main risk factor for bladder cancer was smoking, and the contribution of high fasting plasma glucose increased from 1990 to 2019, with an AAPC of 0.85 in males and 0.61 in females. We predicted total incident cases, deaths and DALYs will increase to 150,372 and 53,520 and 1043,688 in 2030, respectively. The disease burden of bladder cancer in males will consistently higher than that in females from 2020 to 2030. Conclusion: Although mortality and DALYs rates showed downward trends, the disease burden remained heavy in China at present. More effective and long-term health policies are needed to develop for early prevention and treatment of bladder cancer.

Vasculogenic mimicry (VM) constitutes a novel approach for tumour blood supply and contributes to tumour metastasis and poor prognosis in patients with melanoma. Myoferlin (MYOF), a type II membrane protein involved in membrane regeneration and repair, is elevated in several malignant tumours, especially in advanced melanomas. This study aims to investigate the role and mechanism of MYOF in the regulation of VM. VM structures were found in 14 of 52 tested melanoma samples, and high MYOF expression correlated with VM structures. According to Kaplan–Meier survival curves, VM channels and elevated MYOF expression both correlated with poor prognosis in melanoma patients. Down‐regulation of MYOF by siRNA severely impaired the capability of A375 cells to form VM structures in vitro. Further studies demonstrated MYOF knockdown inhibited cell migration and invasion, which is required for VM formation, via decreasing MMP‐2 expression as evidenced by Western blotting, RT‐RCP and ELISA results. SB‐3CT, a specific inhibitor of MMP‐2, showed similar inhibiting effects with siMYOF, further supporting that MYOF down‐regulation inhibits MMP‐2 expression to affect VM formation. Moreover, MYOF knockdown suppress VM formation by A375 cells by inducing mesenchymal‐to‐epithelial transition (MET). After down‐regulating MYOF, focal adhesions were enlarged and A375 cells developed into a clear epithelial morphology. Such cells acquired the expression of E‐cadherin at adherens junctions along with a loss of mesenchymal markers, such as Vimentin and Twist1. In conclusion, MYOF plays an important role in VM and knockdown of MYOF suppresses VM formation via decreasing MMP‐2 and inducing MET in A375 melanoma cells.